AGMB-101
AGMB-101 is a Hepatocyte Growth Factor (HGF)-mimetic antibody that is designed to act through agonism, or stimulation, of the MET receptor.
AGMB-101 has demonstrated both antifibrotic and regenerative activity in preclinical models. HGF is a well-characterized growth factor with key roles in homeostasis and regeneration of multiple organs and tissue. Preclinical experiments have demonstrated that AGMB-101 can mimic the activity of HGF, preventing injury and accelerating tissue regeneration.
We have concluded IND-enabling studies for AGMB-101 and received regulatory clearance to proceed with a Phase 1 single ascending dose trial in healthy participants and patients with liver cirrhosis.
“We are confident that our pipeline will continue to grow with the addition of novel drug candidates that we are designing with the goal of bringing a range of truly disease-modifying treatments to patients in need.”
Philippe Wiesel, Chief Medical Officer
